Clinical Trials Logo
  1. Home
  2. Colitis
  3. NCT06074874
  4. Details
NCT06074874 Clinical Trial

Intestinal Biomarker Analysis After ECP for ICI Colitis

Colitis Clinical Trial

— IBA_ECP  

Official title:
Intestinal Biomarker Analysis After ECP for ICI Colitis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT06074874
Other study ID # ICI_colitis_ECP
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2023
Est. completion date March 30, 2024

Study information
Verified date April 2024
Source University of Freiburg
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the chnages of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.

Description:

It was previously shown that ICI-colitis can be treated with extracorporeal photophoresis. Therefore this retrospective analysis is launched to study the changes of immune cells in the peripheral blood and intestinal tract in an ICI colitis patient cohort. The analysis will include the evaluation of intestinal and peripheral blood biomarkers in patients with ICI colitis receiving ECP as a treatment.

Recruitment information / eligibility
Status Completed
Enrollment 20
Est. completion date March 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ICI colitis Exclusion Criteria: - no informed consent

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Intestinal tissue analysis
Intestinal tissue analysis

Locations
Country Name City State
Germany Freiburg University Medical Center Freiburg Baden Württemberg

Sponsors (1)
Lead Sponsor Collaborator
University of Freiburg

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Apostolova P, Unger S, von Bubnoff D, Meiss F, Becher B, Zeiser R. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy. N Engl J Med. 2020 Jan 16;382(3):294-296. doi: 10.1056/NEJMc1912274. No abstract available. — View Citation

Maas-Bauer K, Kiote-Schmidt C, Bertz H, Apostolova P, Wasch R, Ihorst G, Finke J, Zeiser R. Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplant. 2021 Apr;56(4):909-916. doi: 10.1038/s41409- — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary T cell number and phenotype measurement in the intestinal tract Analysis of CD3+ T cells by flow cytometry 6 months
Secondary T cell number measurement by immunohistochemistry Analysis of CD3+ T cells by immunohistochemistry 6 months
Secondary Analysis of arginase amounts in the intestinal tract using qPCR Analysis of arginase mRNA expression by realtime PCR (qRT-PCR) 6 months
See also
  Status Clinical Trial Phase
Completed NCT00272818 - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Completed NCT01369355 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Phase 3
Completed NCT02709213 - Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
Completed NCT00533078 - Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies Phase 2
Terminated NCT00184171 - Treatment of Microscopic Colitis N/A
Recruiting NCT05333978 - Optoacoustic Detection of Inflammation Using MSOT Device N/A
Not yet recruiting NCT06424769 - Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management N/A
Recruiting NCT02768038 - Intestinal Microbiome and Chronic Inflammatory Bowel Disease
Recruiting NCT04272307 - MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
Completed NCT05514561 - FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
Completed NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease Phase 2
Recruiting NCT02687724 - Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis Phase 4
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01326013 - A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel Phase 2
Not yet recruiting NCT05726396 - A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis Phase 2
Completed NCT05414552 - ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Recruiting NCT04407247 - Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Phase 1/Phase 2
Completed NCT01369342 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) Phase 3
Completed NCT01369329 - A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Phase 3
Terminated NCT00936585 - NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease N/A